| Novel Foxo1-dependent transcriptional programs control Treg cell function W Ouyang, W Liao, CT Luo, N Yin, M Huse, MV Kim, M Peng, P Chan, ... Nature 491 (7425), 554-559, 2012 | 420 | 2012 |
| Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells S Dadi, S Chhangawala, BM Whitlock, RA Franklin, CT Luo, SA Oh, ... Cell 164 (3), 365-377, 2016 | 348 | 2016 |
| Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity CT Luo, W Liao, S Dadi, A Toure, MO Li Nature 529 (7587), 532-536, 2016 | 198 | 2016 |
| Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells W Zhuo, C Luo, X Wang, X Song, Y Fu, Y Luo The Journal of pathology 222 (3), 249-260, 2010 | 101 | 2010 |
| Transcriptional control of regulatory T cell development and function CT Luo, MO Li Trends in immunology 34 (11), 531-539, 2013 | 94 | 2013 |
| Foxo transcription factors in T cell biology and tumor immunity CT Luo, MO Li Seminars in cancer biology 50, 13-20, 2018 | 39 | 2018 |
| miR-182 is largely dispensable for adaptive immunity: lack of correlation between expression and function. JN Pucella, WF Yen, MV Kim, J van der Veeken, CT Luo, ND Socci, ... The Journal of Immunology 194, 2635–2642, 2015 | 32 | 2015 |
| Ets transcription factor GABP controls T cell homeostasis and immunity CT Luo, HU Osmanbeyoglu, MH Do, MR Bivona, A Toure, D Kang, Y Xie, ... Nature Communications 8 (1), 1062, 2017 | 25 | 2017 |
| Compositions and methods for cll1 modification J Lydeard, C Luo, M Lin US Patent App. 17/638,607, 2022 | 1 | 2022 |
| Knock out of CD123 or CLL-1 By CRISPR-Cas9 Editing from Human Hematopoietic Stem Cell Transplants Provide New Possibilities for Increasing Therapeutic Index and Safety for AML … C Luo, G Angelini, S Krishnamurthy, J Lisle, M Isik, A Ghdossi, ... Blood 138, 3818, 2021 | 1 | 2021 |
| VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia J Lydeard, M Lin, C Luo, S Wang, A Halfond, MB Jones, J Scherer, ... Molecular Therapy, 2021 | 1 | 2021 |
| Compositions and methods for cll1 modification J Lydeard, C Luo, M Lin, JE Lisle US Patent App. 18/023,548, 2024 | | 2024 |
| P1429: MULTIPLEX DELETION OF MYELOID ANTIGENS CD33 AND CLL-1 BY CRISPR/CAS9 IN HUMAN HEMATOPOIETIC STEM CELLS HIGHLIGHTS THE POTENTIAL OF NEXT-GENERATION TRANSPLANTS FOR AML … J Xavier-Ferrucio, C Luo, G Angelini, S Krishnamurthy, N Patel, M Pettiglio, ... HemaSphere 6, 1312-1313, 2022 | | 2022 |
| Pre-clinical evaluation, including genomic off-target analysis, of VOR33: a clinic-ready CRISPR/Cas9 engineered hematopoietic stem cell transplant for the treatment of acute … J Lydeard, M Lin, C Luo, S Wang, A Halfond, MB Jones, J Scherer, ... HUMAN GENE THERAPY 32 (19-20), A14-A14, 2021 | | 2021 |
